- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06325137
Transcriptome Analysis in Idiopathic Nephrotic Syndrome: Steroid Responsiveness
Transcriptome Analysis in Idiopathic Nephrotic Syndrome: an Insight Into the Mechanisms of Steroid Responsiveness
Idiopathic nephrotic syndrome (INS) affects the glomerular barrier by damaging the podocytes with foot process effacement, leading to a pathological increase of permeability and protein loss. INS classification is based on the clinical response to glucocorticoid (GC) therapy. When GCs treatment fails to induce remission in a four-six weeks course, patients are defined as affected with steroid-resistant nephrotic syndrome (SRNS).
The whole transcriptome sequencing could consent the INS classification at onset, prior to glucocorticoids (GCs) treatment, allowing to reduction of unuseful GCs treatment. RNA sequencing technologies allow an extensive characterization of the transcriptomic profile and permit global changes in gene expression levels between different conditions such as active and remission of the disease.
Of great interest is the research of a molecular biomarker to predict steroid resistance, a predictor that is not yet available. Among the candidate biomarkers, pharmacogenomic determinants are promising, even if available studies are still limited. Among these, some epigenetic factors have been previously suggested. Data obtained in animal models suggests that nucleotide-binding oligomerization domain-like receptors (NOD-like receptor) pyrin domain containing 3 (NLRP3) inflammasome can be deregulated in a wide variety of glomerular diseases, including those causing INS. Another potential marker involved in steroid response is the long noncoding RNA GAS5. Data reported in the literature indicate that abnormal levels of GAS5 in peripheral blood mononuclear cells (PBMCs) may alter steroid effectiveness in autoimmune diseases, such as inflammatory bowel disease.
Preliminary findings show that the study of NLRP3 promoter methylation could be reduced in the blood of SRNS compared with steroid-sensitive nephrotic syndrome (SSNS) patients. Moreover, unpublished encouraging results on the association between Growth Arrest Specific 5 (GAS5) expression and steroid response in INS in PBMCs were obtained in a preliminary study conducted on 8 patients with the first episode of INS. PBMCs were obtained and GAS5 gene expression was evaluated using TaqMan technology. Patients affected with SRNS presented significantly higher levels of GAS5 in comparison with the SSNS group. In PBMCs from SRNS patients, the GAS5 expression could reduce the availability for binding to GCs target genes of the activated GCs receptor and suppresses GC transcriptional activity.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Marco Pennesi, MD
- Phone Number: +39. 040-3785263
- Email: marco.pennesi@burlo.trieste.it
Study Contact Backup
- Name: Barbara Bonifacio
- Phone Number: +39.040.3785.422
- Email: barbara.bonifacio@burlo.trieste.it
Study Locations
-
-
-
Trieste, Italy, 34137
- Recruiting
- Institute for Maternal and Child Health - IRCCS "Burlo Garofolo"
-
Contact:
- Barbara Bonifacio
- Phone Number: +39.040.3785.422
- Email: barbara.bonifacio@burlo.trieste.it
-
Contact:
- Marco Pennesi, MD
- Phone Number: +39.040-3785263
- Email: marco.pennesi@burlo.trieste.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- clinical diagnosis of INS
- age 1 - 12 years
- signed informed consent by parents or legal guardians
- For controls: aged-matched individuals with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)
Exclusion Criteria:
- Patients aged <1 year or > 12 years
- Patients diagnosed with a secondary or genetic form of NS
- For controls: the presence of coexisting chronic kidney failure, autoimmune or autoinflammatory disease, or endocrinologic disorders.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with steroid-resistant nephrotic syndrome
Identification of a possible molecular signatures at t0 by whole transcriptome analysis from PBMCs
|
A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).
|
Patients with steroid sensitive nephrotic syndrome
Identification of a possible molecular signatures at t0 by whole transcriptome analysis from PBMCs
|
A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Between groups differences in molecular signature by whole transcriptome analysis
Time Frame: At enrolment (T0)
|
A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0)
|
At enrolment (T0)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC 24/2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephrotic Syndrome
-
University of CalgaryUnknownNephrotic Syndrome in Children | Nephrotic Syndrome, Minimal Change | Nephrotic Syndrome,IdiopathicCanada
-
Nationwide Children's HospitalGenentech, Inc.; Emory University; Children's Healthcare of Atlanta; The NephCure...TerminatedSteroid Dependent Nephrotic Syndrome | Frequent Relapsing Nephrotic SyndromeUnited States
-
Seoul National University Childrens HospitalUnknownSteroid Resistant Nephrotic Syndrome | Steroid Dependent Nephrotic SyndromeKorea, Republic of
-
Children's Hospital of Fudan UniversityShanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital...WithdrawnSteroid-Dependent Nephrotic Syndrome | Frequently Relapsing Nephrotic SyndromeChina
-
University Hospital, LimogesHoffmann-La RocheCompletedChildhood Idiopathic Nephrotic SyndromeFrance, Belgium
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Cell Factory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Laboratorio...CompletedIdiopathic Nephrotic Syndrome | Nephrotic Syndrome in Children | Steroid-Dependent Nephrotic SyndromeItaly
-
Assistance Publique - Hôpitaux de ParisRecruitingMinimal Change Nephrotic Syndrome (MCNS)France
-
Astellas Pharma Korea, Inc.CompletedMinimal Change Nephrotic Syndrome (MCNS) | MCNSKorea, Republic of
-
Northwell HealthCompletedIdiopathic Nephrotic Syndrome | Frequently Relapsing Nephrotic SyndromeUnited States
-
Nanjing University School of MedicineCompletedGlucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome:a Prospective Observational StudyNephrotic Syndrome,IdiopathicChina
Clinical Trials on Transcriptome analyses
-
Columbia UniversityRecruitingChildhood Obesity | Morbid ObesityUnited States
-
IRCCS Eugenio MedeaCompleted
-
Nova Scotia Health AuthorityObafemi Awolowo UniversityNot yet recruitingTriple Negative Breast Cancer
-
University Hospital, RouenAssociation Française contre les Myopathies (AFM), ParisCompletedDermatomyositis | PolymyositisFrance
-
Liga Panamericana de Asociaciones de Reumatologia...Janssen Research & Development, LLCRecruiting
-
Peter MacCallum Cancer Centre, AustraliaNational Health and Medical Research Council, Australia; University of MelbourneRecruitingHematologic Diseases | Inherited Platelet Disorder | Inherited BMF SyndromeAustralia
-
Hospices Civils de LyonUnknown
-
Mario Negri Institute for Pharmacological ResearchTerminated
-
Shanghai Jiao Tong University School of MedicineThe First Affiliated Hospital of Nanchang University; The Affiliated Hospital... and other collaboratorsRecruitingAutoimmune GastritisChina
-
IRCCS SYNLAB SDNFondazione Santobono PausiliponRecruitingAcute Lymphoblastic Leukemia, PediatricItaly